Zomedica Announces Second Quarter 2017 Financial Results

Published: Aug 11, 2017

ANN ARBOR, Mich., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and health care solutions company, today reported condensed unaudited interim consolidated financial results for the three and six months ended June 30, 2017. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”).

“We have been actively developing our product pipeline and investigating strategies for domestic and global commercialization,” stated Chairman and CEO Gerald Solensky Jr. “Alongside these business building activities, we are diligently working towards seeking effectiveness of the Form S-1 registration statement from the U.S. Securities and Exchange Commission, in conjunction with approval for listing on the NYSE American.”

Back to news